Recurrence of Cerebral Arteriovenous Malformation Following Complete Obliteration Through Endovascular Embolization
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Arteriovenous malformation (AVM) recurrence after embolization was rarely reported. This study aimed to explore the potential risk factors of recurrence in angiographically obliterated AVMs treated with endovascular embolization. This study reviewed AVMs treated with embolization only in a prospective multicenter registry from August 2011 to December 2021, and ultimately included 92 AVMs who had achieved angiographic obliteration. Recurrence was assessed by follow-up digital subtraction angiography (DSA) or magnetic resonance imaging (MRI). Hazard ratios (HRs) with 95% confidence intervals were calculated using Cox proportional hazards regression models. Nineteen AVMs exhibited recurrence on follow-up imaging. The recurrence rates after complete obliteration at 6 months, 1 year, and 2 years were 4.35%, 9.78%, and 13.0%, respectively. Multivariate Cox regression analysis identified diffuse nidus (HR 3.208, 95% CI 1.030-9.997, p=0.044) as an independent risk factor for recurrence. Kaplan-Meier analysis confirmed a higher cumulative risk of recurrence with diffuse nidus (log-rank, p=0.016). Further, in the exploratory analysis of the effect of embolization timing after AVM rupture on recurrence after the complete obliteration, embolization within 7 days of the hemorrhage was found as an independent risk factor (HR 4.797, 95% CI 1.379-16.689, p=0.014). Kaplan-Meier analysis confirmed that embolization within 7 days of the hemorrhage was associated with a higher cumulative risk of recurrence in ruptured AVMs (log-rank, p<0.0001). This study highlights the significance of diffuse nidus as an independent risk factor for recurrence after complete embolization of AVMs. In addition, we identified a potential recurrent risk associated with early embolization in ruptured AVMs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Translational stroke research - (2023) vom: 13. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hao, Qiang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arteriovenous malformation |
|---|
| Anmerkungen: |
Date Revised 13.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s12975-023-01215-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36449087X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36449087X | ||
| 003 | DE-627 | ||
| 005 | 20231226095537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12975-023-01215-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM36449087X | ||
| 035 | |a (NLM)37957446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hao, Qiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrence of Cerebral Arteriovenous Malformation Following Complete Obliteration Through Endovascular Embolization |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Arteriovenous malformation (AVM) recurrence after embolization was rarely reported. This study aimed to explore the potential risk factors of recurrence in angiographically obliterated AVMs treated with endovascular embolization. This study reviewed AVMs treated with embolization only in a prospective multicenter registry from August 2011 to December 2021, and ultimately included 92 AVMs who had achieved angiographic obliteration. Recurrence was assessed by follow-up digital subtraction angiography (DSA) or magnetic resonance imaging (MRI). Hazard ratios (HRs) with 95% confidence intervals were calculated using Cox proportional hazards regression models. Nineteen AVMs exhibited recurrence on follow-up imaging. The recurrence rates after complete obliteration at 6 months, 1 year, and 2 years were 4.35%, 9.78%, and 13.0%, respectively. Multivariate Cox regression analysis identified diffuse nidus (HR 3.208, 95% CI 1.030-9.997, p=0.044) as an independent risk factor for recurrence. Kaplan-Meier analysis confirmed a higher cumulative risk of recurrence with diffuse nidus (log-rank, p=0.016). Further, in the exploratory analysis of the effect of embolization timing after AVM rupture on recurrence after the complete obliteration, embolization within 7 days of the hemorrhage was found as an independent risk factor (HR 4.797, 95% CI 1.379-16.689, p=0.014). Kaplan-Meier analysis confirmed that embolization within 7 days of the hemorrhage was associated with a higher cumulative risk of recurrence in ruptured AVMs (log-rank, p<0.0001). This study highlights the significance of diffuse nidus as an independent risk factor for recurrence after complete embolization of AVMs. In addition, we identified a potential recurrent risk associated with early embolization in ruptured AVMs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arteriovenous malformation | |
| 650 | 4 | |a Endovascular embolization | |
| 650 | 4 | |a Obliteration | |
| 650 | 4 | |a Recurrence | |
| 700 | 1 | |a Zhang, Haibin |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Heze |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Hengwei |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ruinan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhipeng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Anqi |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Kexin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Qinghui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Runting |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Fa |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chengzhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yukun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Weitao |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Dezhi |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Geng |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Debin |e verfasserin |4 aut | |
| 700 | 1 | |a Pu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Youxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Shibin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaolin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yuanli |e verfasserin |4 aut | |
| 700 | 0 | |a Registry of Multimodality Treatment for Brain Arteriovenous Malformation in Mainland China (MATCH) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational stroke research |d 2010 |g (2023) vom: 13. Nov. |w (DE-627)NLM198739184 |x 1868-601X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:13 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12975-023-01215-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 13 |c 11 | ||